CELL AND GENE THERAPY
ElevateBio | November 25, 2021
ElevateBio, LLC, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced that the United States Patent and Trademark Office has issued US Patent No. 11,162,114 with an anticipated expiry date of June 23, 2040, inclusive of 384 days of patent term adjustment . This patent, issued to LifeEDIT Therapeutics, Inc. is the first to provide composition and methods of use protection for various RNA-guided nucleases in Life Edit’s gene editing platform. Life Edit is an ElevateBio company and holds an array of novel RGNs and base editors.
"This patent issuance marks an important milestone for the Life Edit gene editing platform and is an acknowledgement of the uniqueness of our powerful suite of editing systems. ElevateBio will continue to build and strengthen our portfolio of patents surrounding our enabling platforms, which also include iPSCs, viral vector, and cell and protein engineering, that offer critical technologies and capabilities to facilitate the development of next-generation cell and gene therapies.”
Mitchell Finer, Ph.D., President, R&D of ElevateBio and Chief Executive Officer of Life Edit
This patent is directed to compositions of polynucleotides encoding various RGN polypeptides, CRISPR systems comprising guide RNAs and such RGN polypeptides, as well as methods for binding, cleaving and modifying a target DNA sequence of interest with the use of these novel RGNs and one or more guide RNAs.
About ElevateBio
ElevateBio is a cell and gene therapy technology company designed to power the development and manufacturing of transformative cell and gene therapies. ElevateBio has assembled industry-leading talent, built world-class facilities, and integrated diverse technology platforms necessary to drive innovation and commercialization of cell, gene, and regenerative therapies. ElevateBio has built an initial technology stack, including gene editing, induced pluripotent stem cells, and protein, viral, and cellular engineering, that can be leveraged across the entire portfolio and by strategic partners. At the center of the business model is ElevateBio BaseCamp, a centralized research and development and manufacturing company that offers R&D, process development, and Current Good Manufacturing Practice manufacturing capabilities. ElevateBio is focused on increasing long-term collaborations with industry partners while also developing its own highly innovative cell and gene therapies. ElevateBio's team of scientists, drug developers, and company builders are redefining what it means to be a technology company in the world of drug development, blurring the line between technology and healthcare.
Read More
CELL AND GENE THERAPY
Ocean Genomics, Geninus Inc | March 30, 2021
Ocean Genomics (Pittsburgh, PA), a world chief in AI-based gene expression analysis and RNA biomarker development, and Geninus (Seoul, South Korea), a main full-administration genomics laboratory, report an essential association with the end goal of co-creating RNA-based biomarkers and propelling exploration and clinical applications with emergency clinic, scholastic and biotechnology customers.
The two organizations will dispatch in Korea Ocean Genomics' high level AI-based transcriptome analysis and biomarker stage (txome.ai) as both a cloud-put together and with respect to premises arrangement. Geninus will use the txome.ai stage to extend its CancerSCAN clinical diagnostics stage for its clinic clients, and for biomarker revelation administrations with scholastic and biotechnology customers. Ocean Genomics and Geninus will likewise accomplice on the co-development of a progression of RNA-educated multidimensional biomarkers for research and clinical use.
“We are excited to embark on this partnership with Geninus” said Carl Kingsford, co-founder and CEO, Ocean Genomics. “Ocean Genomics’ expertise in AI and computational method development, together with Geninus’ translational experts and access to data is a powerful combination. Working together, we can advance the field and enhance the uses of RNA biomarkers in clinical and research applications – and provide essential insights for clinicians who care for cancer patients.”
Dr. Woong Yang Park, CEO, Geninus, said, “Genome analysis for precision cancer medicine is becoming an essential process in hospitals. Gene expression analysis on tumor tissue RNA can deliver critical information for targeted therapy and immunotherapy. We expect to advance precision medicine by incorporating Ocean Genomics’ txome.ai into Geninus’ clinical diagnostics platform, CancerSCAN. We look forward to working with Ocean Genomics in co-developing biomarkers and expanding services to our academic and biotechnology customers.”
About Ocean Genomics, Inc.
Ocean Genomics’ mission is to enable drug development and personalized medicine by combining AI with advanced gene-expression analysis to determine rich gene expression signatures and develop RNA-informed multidimensional biomarkers. DNA is a predictor of what might happen in the future, while RNA reveals what’s happening now, making it an essential component in drug development, screening and monitoring, diagnosis and treatment selection. Analyzing RNA requires far more advanced software and computational methods than analyzing DNA.
Ocean Genomics provides the required specialized expertise in AI and transcriptomic analysis and advanced computational software solutions required to power discovery and development programs with life sciences companies and academic researchers. Ocean Genomics provides a self-service, fully configured, cloud-based platform, txome.ai, which provides advanced transcriptome analysis and biomarker generation.
About Geninus Inc.
Geninus provides clinical genome analysis solutions for precision medicine clinics. CancerSCAN, a cancer genome diagnostics platform, is used to inform personalized cancer treatment with targeted therapeutics and immunotherapy in major hospitals in Korea and Japan. CancerSCAN includes an information management system, a bioinformatics pipeline, variant annotation, clinical reports, and datacenter. OncoSTATION, a user interface for CancerSCAN, can be installed within hospital information systems. In addition, Geninus operates a single cell genome analysis platform called Celinus for biomarker discovery. Through collaborations with clinicians and pharmaceutical companies, Celinus can unearth new druggable targets or diagnostic markers in tumor microenvironment cells.
Read More
Eurofins Discovery | November 04, 2020
Eurofins Discovery, the leading provider of services and products to the drug discovery industry, announced a new collaboration with Amphilix AG, a Swiss-based biotech company, to support a program aimed at identifying a treatment modulating key disease mechanisms. Amphilix AG will take advantage of Eurofins Discovery's DiscoveryOne™ offering, an integrated drug discovery platform providing expert support to progress programs to preclinical development and beyond. Amphilix will engage Eurofins Discovery to prosecute the biology, pharmacology, ADME, and safety pharmacology aspects of the program, working in collaboration with the accomplished team at Eurofins Discovery to progress to a development candidate. The two organizations expect this to be the first of multiple programs in which they collaborate to discover new treatments for unmet medical needs.
Read More